

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

**Pegcetacoplan for treating primary complement 3 glomerulopathy and
primary immune-complex membranoproliferative glomerulonephritis in
people 12 years and over ID6489**

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> Swedish Orphan Biovitrum (pegcetacoplan) <p><u>Patient/carers groups</u></p> <ul style="list-style-type: none"> Kidney Care UK Kidney Research UK MPGN/DDD Support Group National Kidney Federation South Asian Health Foundation Specialised Healthcare Alliance <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> Association of Renal Industries British Association of Paediatric Nephrology British Association of Urological Nurses British Association of Urological Surgeons British Society for Immunology Neonatal and Paediatric Pharmacists Group Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Society for DGH Nephrologists UK Clinical Pharmacy Association UK Kidney Association UK Renal Pharmacy Group 	<p><u>General</u></p> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Association of Renal Industries Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation NHS Wales Joint Commissioning Committee Scottish Medicines Consortium Welsh Government <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> Alexion Pharma (eculizumab) Amgen (eculizumab) Novartis (iptacopan) Roche (mycophenolate mofetil) Rosemont Pharmaceuticals (mycophenolate mofetil) Samsung Bioepis (eculizumab) Teva Pharma (mycophenolate mofetil) Tillomed Laboratories (mycophenolate mofetil)

Final stakeholder list for the evaluation of pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over ID6489. Issue date: April 2025.

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<u>Others</u> <ul style="list-style-type: none"> National Renal Complement Therapeutics Centre Department of Health and Social Care NHS England 	<u>Relevant research groups</u> <ul style="list-style-type: none"> Cochrane Kidney and Transplant Group Genomics England MRC Clinical Trials Unit National Institute for Health Research Society for Research in Rehabilitation Wellcome Trust <u>Associated Public Health groups</u> <ul style="list-style-type: none"> Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Final stakeholder list for the evaluation of pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over ID6489. Issue date: April 2025.

Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.